Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutationsHanako Hasegawa, Kenzo Soejima, Katsuhiko Naoki et al.|Lung Cancer|2018Cited by 50
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with CetuximabAyano Oashi, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Therapeutics|2019Cited by 4
Supplementary Figures S1-S11 from Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with CetuximabAyano Oashi, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0
Data from Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with CetuximabAyano Oashi, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0
Supplementary Figures S1-S11 from Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with CetuximabAyano Oashi, Kenzo Soejima, Hiroyuki Yasuda et al.|Unknown|2023Cited by 0